A phase II study of lenalidomide and rituximab (R2) combination in patients with high-risk refractory/relapsed diffuse large B-cell lymphoma
Relapsed/Refractory Diffuse Large B Cell Lymphoma have a dismal prognosis in need of innovative treatments. This prospective phase 2 study enrolled 32 patients between 2013 and 2017 with Relapsed/Refractory Diffuse Large B Cell Lymphoma treated with Rituximab and Lenalidomide (R2). Median age was 69...
Gespeichert in:
| Veröffentlicht in: | Hematology 2023-12, Vol.28 (1), p.2207948-2207948 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2207948 |
|---|---|
| container_issue | 1 |
| container_start_page | 2207948 |
| container_title | Hematology |
| container_volume | 28 |
| creator | Noel, Robin Zemmour, Christophe Montes de Oca, Catalina Belmecheri, Nawel Aurran-Schleinitz, Thérèse Coso, Diane Lopez Almeida, Leonor Mescam, Lénaïg Vey, Norbert Bladé, Jean Sébastien Slama, Borhane Bouabdallah, Reda Schiano de Colella, Jean-Marc |
| description | Relapsed/Refractory Diffuse Large B Cell Lymphoma have a dismal prognosis in need of innovative treatments. This prospective phase 2 study enrolled 32 patients between 2013 and 2017 with Relapsed/Refractory Diffuse Large B Cell Lymphoma treated with Rituximab and Lenalidomide (R2). Median age was 69 years (40-86), 90.1% had received at least 2 prior lines of treatment, 81% were defined as having High Risk disease according to our criteria and ECOG performance status was > 2 in 51.6%. Patients received a median number of 2 cycles of R2 (1-12). With a median follow up of 22.6 months, the objective response rate was 12.5%. Median progression free survival was 2.6 months (95% CI, [1.7-2.9]) and median overall survival was 9.3 months (95% CI, [5.1-Not estimable]). This study therefore did not achieve its primary endpoint and the R2 regimen cannot be recommended in Relapsed/Refractory Diffuse Large B Cell Lymphoma patients with High Risk features. |
| doi_str_mv | 10.1080/16078454.2023.2207948 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1080_16078454_2023_2207948</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_5faa13572f5842b490fbc2b2496eba87</doaj_id><sourcerecordid>2809003920</sourcerecordid><originalsourceid>FETCH-LOGICAL-c464t-ea049c0dee7564376e4c57dc0f44424c850d30adc20e798dab03a5bcedb6f2133</originalsourceid><addsrcrecordid>eNp9kttu1DAQhiMEoqXwCCBfFolsJ45zumOpgK60EhKCa2viw8bFiYOdUPYdeGgcsq3gBt_YGn_zj2bmT5KXGWwyqOEqK6GqWcE2FGi-oRSqhtWPkvMlni4fj_96nyXPQrgFWDB4mpzlVZbHw86TX1sydhgU2e1ImGZ5JE4Tqwa0RrreSEVwkMSbaf5pemzJ5Wf6mgjXt2bAybiBmIGM8aWGKZA7M3WkM4cu9SZ8I15pj2Jy_njllcUxKEmk0XqO5Sz6gyLvUqGsJfbYj53r8XnyRKMN6sXpvki-fnj_5fom3X_6uLve7lPBSjalCoE1AqRSVVGyvCoVE0UlBWjGGGWiLkDmgFJQUFVTS2whx6IVSralprHzi2S36kqHt3z0sTN_5A4N_xNw_sDRT0ZYxQuNmOVFRXVRM9qyBnQraEtZU6oW6ypqvVm1OrT_SN1s99wMQfmeAyvypszYjyzilys-evd9VmHivQnLEHBQbg6c1tAA5A2FiBYrKrwLIQ7zQT4DvniA33uALx7gJw_EvFenEnPbK_mQdb_0CLxdATNo53u8c95KPuHROh83NggTeP7_Gr8BAO_A8w</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2809003920</pqid></control><display><type>article</type><title>A phase II study of lenalidomide and rituximab (R2) combination in patients with high-risk refractory/relapsed diffuse large B-cell lymphoma</title><source>Taylor & Francis Open Access</source><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Noel, Robin ; Zemmour, Christophe ; Montes de Oca, Catalina ; Belmecheri, Nawel ; Aurran-Schleinitz, Thérèse ; Coso, Diane ; Lopez Almeida, Leonor ; Mescam, Lénaïg ; Vey, Norbert ; Bladé, Jean Sébastien ; Slama, Borhane ; Bouabdallah, Reda ; Schiano de Colella, Jean-Marc</creator><creatorcontrib>Noel, Robin ; Zemmour, Christophe ; Montes de Oca, Catalina ; Belmecheri, Nawel ; Aurran-Schleinitz, Thérèse ; Coso, Diane ; Lopez Almeida, Leonor ; Mescam, Lénaïg ; Vey, Norbert ; Bladé, Jean Sébastien ; Slama, Borhane ; Bouabdallah, Reda ; Schiano de Colella, Jean-Marc</creatorcontrib><description>Relapsed/Refractory Diffuse Large B Cell Lymphoma have a dismal prognosis in need of innovative treatments. This prospective phase 2 study enrolled 32 patients between 2013 and 2017 with Relapsed/Refractory Diffuse Large B Cell Lymphoma treated with Rituximab and Lenalidomide (R2). Median age was 69 years (40-86), 90.1% had received at least 2 prior lines of treatment, 81% were defined as having High Risk disease according to our criteria and ECOG performance status was > 2 in 51.6%. Patients received a median number of 2 cycles of R2 (1-12). With a median follow up of 22.6 months, the objective response rate was 12.5%. Median progression free survival was 2.6 months (95% CI, [1.7-2.9]) and median overall survival was 9.3 months (95% CI, [5.1-Not estimable]). This study therefore did not achieve its primary endpoint and the R2 regimen cannot be recommended in Relapsed/Refractory Diffuse Large B Cell Lymphoma patients with High Risk features.</description><identifier>ISSN: 1607-8454</identifier><identifier>ISSN: 1024-5332</identifier><identifier>EISSN: 1607-8454</identifier><identifier>EISSN: 1520-4383</identifier><identifier>DOI: 10.1080/16078454.2023.2207948</identifier><identifier>PMID: 37133334</identifier><language>eng</language><publisher>England: Taylor & Francis</publisher><subject>Aged ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; clinical trial ; Humans ; Lenalidomide - adverse effects ; Life Sciences ; Lymphoma, Large B-Cell, Diffuse ; Lymphoma, Non-Hodgkin - drug therapy ; Prospective Studies ; Relapsed/refractory diffuse large B cell lymphoma ; Rituximab - adverse effects ; rituximab and lenalidomide ; Santé publique et épidémiologie ; Treatment Outcome</subject><ispartof>Hematology, 2023-12, Vol.28 (1), p.2207948-2207948</ispartof><rights>2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group 2023</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c464t-ea049c0dee7564376e4c57dc0f44424c850d30adc20e798dab03a5bcedb6f2133</cites><orcidid>0000-0001-7027-040X ; 0000-0002-7048-5491</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.1080/16078454.2023.2207948$$EPDF$$P50$$Ginformaworld$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.1080/16078454.2023.2207948$$EHTML$$P50$$Ginformaworld$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,860,881,2096,27479,27901,27902,59116,59117</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37133334$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://inserm.hal.science/inserm-04539614$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Noel, Robin</creatorcontrib><creatorcontrib>Zemmour, Christophe</creatorcontrib><creatorcontrib>Montes de Oca, Catalina</creatorcontrib><creatorcontrib>Belmecheri, Nawel</creatorcontrib><creatorcontrib>Aurran-Schleinitz, Thérèse</creatorcontrib><creatorcontrib>Coso, Diane</creatorcontrib><creatorcontrib>Lopez Almeida, Leonor</creatorcontrib><creatorcontrib>Mescam, Lénaïg</creatorcontrib><creatorcontrib>Vey, Norbert</creatorcontrib><creatorcontrib>Bladé, Jean Sébastien</creatorcontrib><creatorcontrib>Slama, Borhane</creatorcontrib><creatorcontrib>Bouabdallah, Reda</creatorcontrib><creatorcontrib>Schiano de Colella, Jean-Marc</creatorcontrib><title>A phase II study of lenalidomide and rituximab (R2) combination in patients with high-risk refractory/relapsed diffuse large B-cell lymphoma</title><title>Hematology</title><addtitle>Hematology</addtitle><description>Relapsed/Refractory Diffuse Large B Cell Lymphoma have a dismal prognosis in need of innovative treatments. This prospective phase 2 study enrolled 32 patients between 2013 and 2017 with Relapsed/Refractory Diffuse Large B Cell Lymphoma treated with Rituximab and Lenalidomide (R2). Median age was 69 years (40-86), 90.1% had received at least 2 prior lines of treatment, 81% were defined as having High Risk disease according to our criteria and ECOG performance status was > 2 in 51.6%. Patients received a median number of 2 cycles of R2 (1-12). With a median follow up of 22.6 months, the objective response rate was 12.5%. Median progression free survival was 2.6 months (95% CI, [1.7-2.9]) and median overall survival was 9.3 months (95% CI, [5.1-Not estimable]). This study therefore did not achieve its primary endpoint and the R2 regimen cannot be recommended in Relapsed/Refractory Diffuse Large B Cell Lymphoma patients with High Risk features.</description><subject>Aged</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>clinical trial</subject><subject>Humans</subject><subject>Lenalidomide - adverse effects</subject><subject>Life Sciences</subject><subject>Lymphoma, Large B-Cell, Diffuse</subject><subject>Lymphoma, Non-Hodgkin - drug therapy</subject><subject>Prospective Studies</subject><subject>Relapsed/refractory diffuse large B cell lymphoma</subject><subject>Rituximab - adverse effects</subject><subject>rituximab and lenalidomide</subject><subject>Santé publique et épidémiologie</subject><subject>Treatment Outcome</subject><issn>1607-8454</issn><issn>1024-5332</issn><issn>1607-8454</issn><issn>1520-4383</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>0YH</sourceid><sourceid>EIF</sourceid><sourceid>DOA</sourceid><recordid>eNp9kttu1DAQhiMEoqXwCCBfFolsJ45zumOpgK60EhKCa2viw8bFiYOdUPYdeGgcsq3gBt_YGn_zj2bmT5KXGWwyqOEqK6GqWcE2FGi-oRSqhtWPkvMlni4fj_96nyXPQrgFWDB4mpzlVZbHw86TX1sydhgU2e1ImGZ5JE4Tqwa0RrreSEVwkMSbaf5pemzJ5Wf6mgjXt2bAybiBmIGM8aWGKZA7M3WkM4cu9SZ8I15pj2Jy_njllcUxKEmk0XqO5Sz6gyLvUqGsJfbYj53r8XnyRKMN6sXpvki-fnj_5fom3X_6uLve7lPBSjalCoE1AqRSVVGyvCoVE0UlBWjGGGWiLkDmgFJQUFVTS2whx6IVSralprHzi2S36kqHt3z0sTN_5A4N_xNw_sDRT0ZYxQuNmOVFRXVRM9qyBnQraEtZU6oW6ypqvVm1OrT_SN1s99wMQfmeAyvypszYjyzilys-evd9VmHivQnLEHBQbg6c1tAA5A2FiBYrKrwLIQ7zQT4DvniA33uALx7gJw_EvFenEnPbK_mQdb_0CLxdATNo53u8c95KPuHROh83NggTeP7_Gr8BAO_A8w</recordid><startdate>20231231</startdate><enddate>20231231</enddate><creator>Noel, Robin</creator><creator>Zemmour, Christophe</creator><creator>Montes de Oca, Catalina</creator><creator>Belmecheri, Nawel</creator><creator>Aurran-Schleinitz, Thérèse</creator><creator>Coso, Diane</creator><creator>Lopez Almeida, Leonor</creator><creator>Mescam, Lénaïg</creator><creator>Vey, Norbert</creator><creator>Bladé, Jean Sébastien</creator><creator>Slama, Borhane</creator><creator>Bouabdallah, Reda</creator><creator>Schiano de Colella, Jean-Marc</creator><general>Taylor & Francis</general><general>Maney Publishing</general><general>Taylor & Francis Group</general><scope>0YH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>1XC</scope><scope>VOOES</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-7027-040X</orcidid><orcidid>https://orcid.org/0000-0002-7048-5491</orcidid></search><sort><creationdate>20231231</creationdate><title>A phase II study of lenalidomide and rituximab (R2) combination in patients with high-risk refractory/relapsed diffuse large B-cell lymphoma</title><author>Noel, Robin ; Zemmour, Christophe ; Montes de Oca, Catalina ; Belmecheri, Nawel ; Aurran-Schleinitz, Thérèse ; Coso, Diane ; Lopez Almeida, Leonor ; Mescam, Lénaïg ; Vey, Norbert ; Bladé, Jean Sébastien ; Slama, Borhane ; Bouabdallah, Reda ; Schiano de Colella, Jean-Marc</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c464t-ea049c0dee7564376e4c57dc0f44424c850d30adc20e798dab03a5bcedb6f2133</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Aged</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>clinical trial</topic><topic>Humans</topic><topic>Lenalidomide - adverse effects</topic><topic>Life Sciences</topic><topic>Lymphoma, Large B-Cell, Diffuse</topic><topic>Lymphoma, Non-Hodgkin - drug therapy</topic><topic>Prospective Studies</topic><topic>Relapsed/refractory diffuse large B cell lymphoma</topic><topic>Rituximab - adverse effects</topic><topic>rituximab and lenalidomide</topic><topic>Santé publique et épidémiologie</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Noel, Robin</creatorcontrib><creatorcontrib>Zemmour, Christophe</creatorcontrib><creatorcontrib>Montes de Oca, Catalina</creatorcontrib><creatorcontrib>Belmecheri, Nawel</creatorcontrib><creatorcontrib>Aurran-Schleinitz, Thérèse</creatorcontrib><creatorcontrib>Coso, Diane</creatorcontrib><creatorcontrib>Lopez Almeida, Leonor</creatorcontrib><creatorcontrib>Mescam, Lénaïg</creatorcontrib><creatorcontrib>Vey, Norbert</creatorcontrib><creatorcontrib>Bladé, Jean Sébastien</creatorcontrib><creatorcontrib>Slama, Borhane</creatorcontrib><creatorcontrib>Bouabdallah, Reda</creatorcontrib><creatorcontrib>Schiano de Colella, Jean-Marc</creatorcontrib><collection>Taylor & Francis Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Noel, Robin</au><au>Zemmour, Christophe</au><au>Montes de Oca, Catalina</au><au>Belmecheri, Nawel</au><au>Aurran-Schleinitz, Thérèse</au><au>Coso, Diane</au><au>Lopez Almeida, Leonor</au><au>Mescam, Lénaïg</au><au>Vey, Norbert</au><au>Bladé, Jean Sébastien</au><au>Slama, Borhane</au><au>Bouabdallah, Reda</au><au>Schiano de Colella, Jean-Marc</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A phase II study of lenalidomide and rituximab (R2) combination in patients with high-risk refractory/relapsed diffuse large B-cell lymphoma</atitle><jtitle>Hematology</jtitle><addtitle>Hematology</addtitle><date>2023-12-31</date><risdate>2023</risdate><volume>28</volume><issue>1</issue><spage>2207948</spage><epage>2207948</epage><pages>2207948-2207948</pages><issn>1607-8454</issn><issn>1024-5332</issn><eissn>1607-8454</eissn><eissn>1520-4383</eissn><abstract>Relapsed/Refractory Diffuse Large B Cell Lymphoma have a dismal prognosis in need of innovative treatments. This prospective phase 2 study enrolled 32 patients between 2013 and 2017 with Relapsed/Refractory Diffuse Large B Cell Lymphoma treated with Rituximab and Lenalidomide (R2). Median age was 69 years (40-86), 90.1% had received at least 2 prior lines of treatment, 81% were defined as having High Risk disease according to our criteria and ECOG performance status was > 2 in 51.6%. Patients received a median number of 2 cycles of R2 (1-12). With a median follow up of 22.6 months, the objective response rate was 12.5%. Median progression free survival was 2.6 months (95% CI, [1.7-2.9]) and median overall survival was 9.3 months (95% CI, [5.1-Not estimable]). This study therefore did not achieve its primary endpoint and the R2 regimen cannot be recommended in Relapsed/Refractory Diffuse Large B Cell Lymphoma patients with High Risk features.</abstract><cop>England</cop><pub>Taylor & Francis</pub><pmid>37133334</pmid><doi>10.1080/16078454.2023.2207948</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0001-7027-040X</orcidid><orcidid>https://orcid.org/0000-0002-7048-5491</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1607-8454 |
| ispartof | Hematology, 2023-12, Vol.28 (1), p.2207948-2207948 |
| issn | 1607-8454 1024-5332 1607-8454 1520-4383 |
| language | eng |
| recordid | cdi_crossref_primary_10_1080_16078454_2023_2207948 |
| source | Taylor & Francis Open Access; MEDLINE; DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Aged Antineoplastic Combined Chemotherapy Protocols - adverse effects clinical trial Humans Lenalidomide - adverse effects Life Sciences Lymphoma, Large B-Cell, Diffuse Lymphoma, Non-Hodgkin - drug therapy Prospective Studies Relapsed/refractory diffuse large B cell lymphoma Rituximab - adverse effects rituximab and lenalidomide Santé publique et épidémiologie Treatment Outcome |
| title | A phase II study of lenalidomide and rituximab (R2) combination in patients with high-risk refractory/relapsed diffuse large B-cell lymphoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T03%3A44%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20phase%20II%20study%20of%20lenalidomide%20and%20rituximab%20(R2)%20combination%20in%20patients%20with%20high-risk%20refractory/relapsed%20diffuse%20large%20B-cell%20lymphoma&rft.jtitle=Hematology&rft.au=Noel,%20Robin&rft.date=2023-12-31&rft.volume=28&rft.issue=1&rft.spage=2207948&rft.epage=2207948&rft.pages=2207948-2207948&rft.issn=1607-8454&rft.eissn=1607-8454&rft_id=info:doi/10.1080/16078454.2023.2207948&rft_dat=%3Cproquest_cross%3E2809003920%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2809003920&rft_id=info:pmid/37133334&rft_doaj_id=oai_doaj_org_article_5faa13572f5842b490fbc2b2496eba87&rfr_iscdi=true |